- Myriad Genetics (MYGN) jumped nearly 11.5% today on news its Prolaris genetic testing method proved effective in predicting which men would see a cancer recurrence following radical prostate surgery (also).
- A study published in the Journal of Urology said a test which evaluated more than 5,000 patients across 11 clinical studies showed Prolaris proved more effective in predicting the likelihood that cancer would return than a Gleason Score or PSA test.
- The study "represents a great advance in the treatment of prostate cancer," according to the study investigator.
Myriad Genetics' Prolaris effective in detecting recurring prostate cancer
Feb 18 2014, 18:45 ET